Vantage Point

Our latest thinking on biopharmaceutical development and commercialization.

John Procter

The ingredients of successful adherence interventions to support patients
John Procter discusses the role biopharma can play in improving medication adherence.

Quintiles Blog

Fresh ideas and insights from our experts around the globe


Topics to Explore


Advances in genomics and information technology are ushering in a new era for oncology drug development, but biopharmaceutical companies must move the conversation from cost to value.

Rare Diseases

50% childrenAlthough regulatory incentives and the designation of “orphan” products have stimulated commercial research for rare diseases, their low prevalence, high complexity and predominance in children create significant barriers. Providers and patients are clamoring for treatment access and improved outcomes, but increasingly payers are making hard choices about reimbursing these therapies.

Evidence & Value

Healthcare costs are climbing, regulators around the globe are requiring more information, and both providers and payers have higher expectations for a medical treatment’s proof of value before prescribing or paying for those treatments.

Payers & Providers

Payers and providers are steadily beginning to only pay for and prescribe treatments that improve patient outcomes, and despite how good a new product might be, it is only as good as how it is used in a real-world setting.


366 million...As the prevalence of diabetes continues to increase globally, and the market for new therapies grows increasingly crowded, it's more important than ever to match the right drug to the right patient.


Biosimilar development and commercialization is a uniquely difficult endeavor requiring precise, stepwise planning to ensure timely regulatory approval and optimal market access. 


The healthcare industry is in a radical state of transformation, and biopharma players need to adapt to a systems-oriented approach to protect revenues, grow market share, and obtain regulatory approval for new treatments.

Peer-Reviewed Publications
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.
Ann Rheum Dis. 2015 Jun;74(6):979-84.
Read more
A comparison of models for predicting early hospital readmissions.
J Biomed Inform. 2015 Jun 1.
Read more
American Society of Hypertension Scientific Statements Addressing Resistant Hypertension.
J Clin Hypertens (Greenwich). 2015 Jul 14
Read more
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Lancet. 2015 Jun 6;385(9984):2288-95.
Read more
Balancing the interests of patient data protection and medication safety monitoring in a public-private partnership.
JMIR Med Inform. 2015 Apr 15;3(2)
Read more